A. Brander, P. Viikinkoski, J. Nickels, and L. Kivisaari, Thyroid gland: US screening in a random adult population., Radiology, vol.181, issue.3, pp.683-690, 1991.
DOI : 10.1148/radiology.181.3.1947082

S. Ezzat, D. Sarti, D. Cain, and G. Braunstein, Thyroid incidentalomas. Prevalence by palpation and ultrasonography. Archives of Internal Medicine, pp.1838-1878, 1994.

M. Colonna, P. Grosclaude, L. Remontet, C. Schvartz, J. Mace-lesech et al., Incidence of thyroid cancer in adults recorded by French cancer registries (1978???1997), European Journal of Cancer, vol.38, issue.13, 2002.
DOI : 10.1016/S0959-8049(02)00110-7

A. Belot, M. Velten, P. Grosclaude, N. Bossard, G. Launoy et al., Estimation nationale de l'incidence et de la mortalité par cancer en France entre, 1980.

L. Davies and H. Welch, Increasing Incidence of Thyroid Cancer in the United States, 1973-2002, JAMA, vol.295, issue.18, pp.2164-2171, 1973.
DOI : 10.1001/jama.295.18.2164

C. Estaquio, K. Castetbon, P. Valeix, S. Maladies-thyroïdiennes-dans-la-cohorte, . Vi et al., Estimation de leur incidence et des facteurs de risque associés, 1994.

E. Hindié, L. Leenhardt, F. Vitaux, N. Colas-linhart, P. Grosclaude et al., Non-medical exposure to radioiodines and thyroid cancer, European Journal of Nuclear Medicine and Molecular Imaging, vol.29, issue.S2, 2002.
DOI : 10.1007/s00259-002-0912-4

G. Russ, B. Royer, C. Bigorgne, A. Rouxel, M. Bienvenu-perrard et al., Prospective evaluation of thyroid imaging reporting and data system on 4550 nodules with and without elastography, European Journal of Endocrinology, vol.168, issue.5, pp.649-55, 2013.
DOI : 10.1530/EJE-12-0936

E. Cibas and S. Ali, The Bethesda System for Reporting Thyroid Cytopathology, American Journal of Clinical Pathology, vol.132, issue.5, pp.658-65, 2009.
DOI : 10.1309/AJCPPHLWMI3JV4LA

C. Hedinger, E. Williams, and L. Sobin, Histological Typing of Thyroid Tumour, 1993.
DOI : 10.1007/978-3-642-61383-8

M. Xing, R. Bryan, M. Haugen, and . Schlumberger, Progress in molecular-based management of differentiated thyroid cancer, The Lancet, vol.381, issue.9871, pp.1058-69, 2013.
DOI : 10.1016/S0140-6736(13)60109-9

L. Sobin, M. Gospodarowicz, and C. Wittekind, TNM Classification of Malignant Tumours, 2009.
DOI : 10.1002/0471463752

F. Pacini, European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium, European Journal of Endocrinology, vol.154, issue.6, pp.787-803, 2006.
DOI : 10.1530/eje.1.02158

D. Cooper, G. Doherty, B. Haugen, B. Hauger, R. Kloos et al., Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer, Thyroid, vol.19, issue.11, pp.1167-214, 2009.
DOI : 10.1089/thy.2009.0110

K. Bilimoria, D. Bentrem, C. Ko, A. Stewart, D. Winchester et al., Extent of Surgery Affects Survival for Papillary Thyroid Cancer. Annals of Surgery, pp.375-84, 2007.

G. Randolph and G. Daniels, Radioactive Iodine Lobe Ablation as an Alternative to Completion Thyroidectomy for Follicular Carcinoma of the Thyroid, Thyroid, vol.12, issue.11, pp.989-96, 2002.
DOI : 10.1089/105072502320908321

R. Ciappuccini, N. Heutte, G. Trzepla, J. Rame, D. Vaur et al., Postablation 131I scintigraphy with neck and thorax SPECT-CT and stimulated serum thyroglobulin level predict the outcome of patients with differentiated thyroid cancer, European Journal of Endocrinology, vol.164, issue.6, pp.961-970, 2011.
DOI : 10.1530/EJE-11-0156

E. Mazzaferri and S. Jhiang, Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer, The American Journal of Medicine, vol.97, issue.5, pp.418-446, 1994.
DOI : 10.1016/0002-9343(94)90321-2

E. Hindié, D. Mellière, F. Lange, I. Hallaj, C. De-labriolle-vaylet et al., Functioning pulmonary metastases of thyroid cancer: does radioiodine influence the prognosis?, European Journal of Nuclear Medicine and Molecular Imaging, vol.30, issue.7, pp.974-81, 2003.
DOI : 10.1007/s00259-003-1174-5

C. Durante, N. Haddy, E. Baudin, S. Leboulleux, D. Hartl et al., Long-Term Outcome of 444 Patients with Distant Metastases from Papillary and Follicular Thyroid Carcinoma: Benefits and Limits of Radioiodine Therapy, The Journal of Clinical Endocrinology & Metabolism, vol.91, issue.8, pp.2892-2901, 2006.
DOI : 10.1210/jc.2005-2838

URL : https://hal.archives-ouvertes.fr/hal-00176664

E. Hindié, P. Zanotti-fregonara, I. Keller, F. Duron, J. Devaux et al., Bone metastases of differentiated thyroid cancer: impact of early 131I-based detection on outcome, Endocrine Related Cancer, vol.14, issue.3, pp.799-807, 2007.
DOI : 10.1677/ERC-07-0120

D. Taïeb, F. Sebag, M. Cherenko, K. Baumstarck-barrau, C. Fortanier et al., Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled study, Clinical Endocrinology, vol.16, issue.1, pp.115-138, 2009.
DOI : 10.1111/j.1365-2265.2008.03424.x

M. Schlumberger, B. Catargi, I. Borget, D. Déandreis, S. Zerdoud et al., Strategies of Radioiodine Ablation in Patients with Low-Risk Thyroid Cancer, New England Journal of Medicine, vol.366, issue.18, pp.1663-73, 2012.
DOI : 10.1056/NEJMoa1108586

URL : https://hal.archives-ouvertes.fr/hal-00942194

U. Mallick, C. Harmer, B. Yap, J. Wadsley, S. Clarke et al., Ablation with Low-Dose Radioiodine and Thyrotropin Alfa in Thyroid Cancer, New England Journal of Medicine, vol.366, issue.18, pp.3661674-85
DOI : 10.1056/NEJMoa1109589

D. Van-nostrand, F. Atkins, F. Yeganeh, E. Acio, R. Bursaw et al., Dosimetrically Determined Doses of Radioiodine for the Treatment of Metastatic Thyroid Carcinoma, Thyroid, vol.12, issue.2, pp.121-155, 2002.
DOI : 10.1089/105072502753522356

R. Tuttle, R. Leboeuf, R. Robbins, R. Qualey, K. Pentlow et al., Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer, Journal of Nuclear Medicine, vol.47, issue.10, pp.1587-91, 2006.

D. Taïeb, T. Jacob, E. Zotian, and O. Mundler, Lack of Efficacy of Recombinant Human Thyrotropin Versus Thyroid Hormone Withdrawal for Radioiodine Therapy Imaging in a Patient with Differentiated Thyroid Carcinoma Lung Metastases, Thyroid, vol.14, issue.6, pp.465-472, 2004.
DOI : 10.1089/105072504323150804

P. Zanotti-fregonara and E. Hindié, On the effectiveness of recombinant human TSH as a stimulating agent for 131I treatment of metastatic differentiated thyroid cancer, European Journal of Nuclear Medicine and Molecular Imaging, vol.154, issue.12, pp.2264-2270, 2010.
DOI : 10.1007/s00259-010-1608-9

L. Freudenberg, W. Jentzen, T. Petrich, C. Frömke, R. Marlowe et al., Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124I PET/CT dosimetric comparisons, European Journal of Nuclear Medicine and Molecular Imaging, vol.45, issue.12, 2010.
DOI : 10.1007/s00259-010-1565-3

S. Leboulleux, D. Deandreis, J. Lumbroso, E. Baudin, and M. Schlumberger, Cancers de la thyroïde et traitement par iode 131. Medecine Nucleaire, pp.172-180, 2014.
DOI : 10.1016/j.mednuc.2014.03.132

E. Sociécéte-francaise-de-physique-médicale-sfsapir, Z. Keidar, J. Sachs, A. Engel, L. Bettman et al., Contrôle de qualité et mesure des performances des gamma-caméras. Rapport SFPM n°28 The new technology of combined transmission and emission tomography in evaluation of endocrine neoplasms, Journal of Nuclear Medicine, vol.42, issue.7, pp.998-1004, 2001.

K. Tharp, O. Israel, J. Hausmann, and L. Bettman, Impact of 131I-SPECT/CT images obtained with an integrated system in the follow-up of patients with thyroid carcinoma. ? and molecular imaging, 2004.

D. Glazer, R. Brown, K. Wong, H. Savas, M. Gross et al., SPECT/CT Evaluation of Unusual Physiologic Radioiodine Biodistributions: Pearls and Pitfalls in Image Interpretation, RadioGraphics, vol.33, issue.2, pp.397-418, 2013.
DOI : 10.1148/rg.332125051

L. Chen, Q. Luo, Y. Shen, Y. Yu, Z. Yuan et al., Incremental Value of 131I SPECT/CT in the Management of Patients with Differentiated Thyroid Carcinoma, Journal of Nuclear Medicine, vol.49, issue.12, 2008.
DOI : 10.2967/jnumed.108.052399

N. Aide, N. Heutte, J. Rame, E. Rousseau, C. Loiseau et al., I Scintigraphy for Thyroid Cancer, The Journal of Clinical Endocrinology & Metabolism, vol.94, issue.6, pp.2075-84, 2009.
DOI : 10.1210/jc.2008-2313

M. Mustafa, T. Kuwert, K. Weber, P. Knesewitsch, T. Negele et al., Regional lymph node involvement in T1 papillary thyroid carcinoma: a bicentric prospective SPECT/CT study, European Journal of Nuclear Medicine and Molecular Imaging, vol.19, issue.6, pp.1462-1468, 2010.
DOI : 10.1007/s00259-010-1408-2

D. Schmidt, A. Szikszai, R. Linke, W. Bautz, and T. Kuwert, Impact of 131I SPECT/Spiral CT on Nodal Staging of Differentiated Thyroid Carcinoma at the First Radioablation, Journal of Nuclear Medicine, vol.50, issue.1, pp.18-23, 2008.
DOI : 10.2967/jnumed.108.052746

S. Kohlfuerst, I. Igerc, M. Lobnig, H. Gallowitsch, I. Gomez-segovia et al., Posttherapeutic 131I SPECT-CT offers high diagnostic accuracy when the findings on conventional planar imaging are inconclusive and allows a tailored patient treatment regimen, European Journal of Nuclear Medicine and Molecular Imaging, vol.12, issue.6, pp.886-93, 2009.
DOI : 10.1007/s00259-008-1044-2

A. Avram, L. Fig, K. Frey, M. Gross, and K. Wong, Preablation 131-I Scans With SPECT/CT in Postoperative Thyroid Cancer Patients: What Is the Impact on Staging? The Journal of Clinical Endocrinology & Metabolism, pp.1163-71, 2013.

D. Schmidt, R. Linke, M. Uder, and T. Kuwert, Five months??? follow-up of patients with and without iodine-positive lymph node metastases of thyroid carcinoma as disclosed by 131I-SPECT/CT at the first radioablation, European Journal of Nuclear Medicine and Molecular Imaging, vol.36, issue.4, pp.699-705, 2009.
DOI : 10.1007/s00259-009-1299-2

O. De-dreuille, P. Maszelin, H. Foehrenbach, G. Bonardel, and J. Gaillard, Principe et technique de la tomographie par émission de positons (TEP). EMC -Radiologie, pp.2-35, 2003.

V. Kapoor, B. Mccook, and F. Torok, An Introduction to PET-CT Imaging1, RadioGraphics, 2004.

J. Vuillez, Biologie du FDG et des autres traceurs émetteurs de positons utilisés en cancérologie. Rev Acomen, 1998.

O. Warburg, On the Origin of Cancer Cells. Science, Feb, vol.24123, issue.3191, pp.309-323, 1956.

T. Abraham and H. Schöder, Thyroid Cancer?Indications and TEP Abraham nuclear medicine, pp.121-159, 2011.

J. Deichen, C. Schmidt, O. Prante, S. Maschauer, A. R. Börner et al., Influence of TSH on uptake of [18F] fluorodeoxyglucose in human thyroid cells in vitro Influence of rhTSH on [18 F]fluorodeoxyglucose uptake by differentiated thyroid carcinoma, European journal of Nuclear Medicine and Molecular Imaging European Journal of Nuclear Medicine and Molecular Imaging, 2002.

S. Leboulleux, P. Schroeder, N. Busaidy, A. Auperin, C. Corone et al., -Glucose Positron Emission Tomography/Computed Tomography Imaging to Localize Residual Differentiated Thyroid Cancer, The Journal of Clinical Endocrinology & Metabolism, vol.94, issue.4, pp.1310-1316, 2009.
DOI : 10.1210/jc.2008-1747

URL : https://hal.archives-ouvertes.fr/hal-01160298

J. Lee, S. Lee, D. Lee, and Y. Kim, Clinical Utility of 18F-FDG PET/CT Concurrent with 131I Therapy in Intermediate-to-High-Risk Patients with Differentiated Thyroid Cancer: Dual-Center Experience with 286 Patients, Journal of Nuclear Medicine, vol.54, issue.8, pp.1230-1236, 2013.
DOI : 10.2967/jnumed.112.117119

S. Leboulleux, B. El, I. Borget, I. Elleuch, M. Déandreis et al., Postradioiodine Treatment Whole-Body Scan in the Era of 18-Fluorodeoxyglucose Positron Emission Tomography for Differentiated Thyroid Carcinoma with Elevated Serum Thyroglobulin Levels, Thyroid, vol.22, issue.8, 2012.
DOI : 10.1089/thy.2012.0081

E. Ozkan, G. Aras, and N. Kucuk, Correlation of 18F-FDG PET/CT Findings With Histopathological Results in Differentiated Thyroid Cancer Patients Who Have Increased Thyroglobulin or Antithyroglobulin Antibody Levels and Negative 131I Whole-Body Scan Results, Clinical Nuclear Medicine, vol.38, issue.5, pp.326-357, 2013.
DOI : 10.1097/RLU.0b013e318286827b

H. Palmedo, J. Bucerius, A. Joe, H. Strunk, N. Hortling et al., Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management, Journal of Nuclear Medicine, vol.47, issue.4, pp.616-640, 2006.

M. Miller, Q. Chen, D. Elashoff, E. Abemayor, S. John et al., Positron emission tomography and positron emission tomography-CT evaluation for r e c u r r e n t p a p i l l a r y t h y r o i d c a r c i n o m a : M e t a -analysis and literature review, Head Neck, pp.562-567, 2011.

B. Helal, P. Merlet, M. Toubert, B. Franc, C. Schvartz et al., Clinical impact of 18F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative 131I scanning results after therapy, Journal of Nuclear Medicine. Soc Nuclear Med, issue.10, pp.421464-421473, 2001.

W. Wang, S. Larson, M. Fazzari, S. Tickoo, K. Kolbert et al., Prognostic Value of [18F]Fluorodeoxyglucose Positron Emission Tomographic Scanning in Patients with Thyroid Cancer, Journal of Clinical Endocrinology & Metabolism, vol.85, issue.3, pp.1107-1120, 2000.
DOI : 10.1210/jc.85.3.1107

S. Rosenbaum-krumme, R. Görges, A. Bockisch, I. Binse, . 18f-fdg et al., 18F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy, European Journal of Nuclear Medicine and Molecular Imaging, vol.9, issue.3, pp.1373-80, 2012.
DOI : 10.1007/s00259-012-2065-4

A. Ho, R. Grewal, R. Leboeuf, E. Sherman, D. Pfister et al., Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer, New England Journal of Medicine, vol.368, issue.7, pp.623-655, 2013.
DOI : 10.1056/NEJMoa1209288

J. Lee, J. Choi, Y. Choi, S. Hyun, S. Moon et al., F-Fluorodeoxyglucose Positron Emission Tomography in Subjects without Cancer History, Korean Journal of Radiology, vol.14, issue.3, p.501, 2013.
DOI : 10.3348/kjr.2013.14.3.501

F. Bertagna, G. Treglia, A. Piccardo, E. Giovannini, G. Bosio et al., CT thyroid incidentalomas: a wide retrospective analysis in three Italian centres on the significance of focal uptake and SUV value 18-Fluorodeoxyglucose Positron Emission Tomography in the Early Diagnostic Workup of Differentiated Thyroid Cancer Patients with a Negative Post-Therapeutic Iodine Scan and Detectable Thyroglobulin, Endocrine. Thyroid, vol.4323, issue.38, pp.678-85, 2013.

K. Wong, N. Zarzhevsky, J. Cahill, K. Frey, and A. Avram, Incremental Value of Diagnostic 131I SPECT/CT Fusion Imaging in the Evaluation of Differentiated Thyroid Carcinoma, American Journal of Roentgenology, vol.191, issue.6, pp.1785-94, 2008.
DOI : 10.2214/AJR.08.1218

K. Wong, J. Sisson, K. Koral, K. Frey, and A. Avram, I SPECT/CT, American Journal of Roentgenology, vol.195, issue.3, pp.730-736, 2010.
DOI : 10.2214/AJR.09.3458

M. Menges, M. Uder, T. Kuwert, and D. Schmidt, 131I SPECT/CT in the Follow-Up of Patients With Differentiated Thyroid Carcinoma, Clinical Nuclear Medicine, vol.37, issue.6, pp.555-60
DOI : 10.1097/RLU.0b013e3182531dca

M. Schlumberger, Cancer papillaire et??folliculaire de??la??thyro??de, Annales d'Endocrinologie, vol.68, issue.2-3, pp.120-128, 2007.
DOI : 10.1016/j.ando.2007.04.004

D. Deandreis, G. Al, A. Leboulleux, S. Lacroix, L. Garsi et al., Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome? Endocrine Related Cancer, pp.159-69, 2010.

S. Rosenbaum-krumme, R. Görges, A. Bockisch, I. Binse, . 18f-fdg et al., 18F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy, European Journal of Nuclear Medicine and Molecular Imaging, vol.9, issue.3, pp.1373-80, 2012.
DOI : 10.1007/s00259-012-2065-4

E. Labrador, A. Burillo, J. Castell-conesa, G. Alfonso, N. González et al., Positron emission tomography-computed tomography with 18F-fluorodeoxyglucose in patients with recurrent differentiated thyroid carcinoma and negative radioiodine scan. Diagnostic performance and relation with thyroglobulin levels